-
Tytuł:
-
Effects of chronic scopolamine treatment on cognitive impairment and neurofilament expression in the mouse hippocampus.
-
Autorzy:
-
Lee JC; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Park JH; Department of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea.
Ahn JH; Department of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea.
Park J; Department of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea.
Kim IH; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Cho JH; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Shin BN; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Lee TK; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Kim H; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Song M; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Cho GS; Pharmacology and Toxicology Department, Shinpoong Pharmaceutical Co., Ltd., Ansan, Gyeonggi 15610, Republic of Korea.
Kim DW; Department of Biochemistry and Molecular Biology, College of Dentistry, Kangnung‑Wonju National University, Gangneung, Gangwon 25457, Republic of Korea.
Kang IJ; Department of Food Science and Nutrition, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea.
Kim YM; Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Won MH; Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea.
Choi SY; Department of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon, Gangwon 24252, Republic of Korea.
-
Źródło:
-
Molecular medicine reports [Mol Med Rep] 2018 Jan; Vol. 17 (1), pp. 1625-1632. Date of Electronic Publication: 2017 Nov 15.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Athens, Greece : D. A. Spandidos
-
MeSH Terms:
-
Cognitive Dysfunction/*drug therapy
Hippocampus/*drug effects
Intermediate Filaments/*pathology
Muscarinic Antagonists/*therapeutic use
Neurofilament Proteins/*analysis
Scopolamine/*therapeutic use
Animals ; Cognitive Dysfunction/pathology ; Hippocampus/pathology ; Male ; Mice ; Mice, Inbred ICR
-
References:
-
Bioessays. 2003 Apr;25(4):346-55. (PMID: 12655642)
J Neurol Sci. 1993 Nov;119(2):217-28. (PMID: 8277338)
Neurosci Biobehav Rev. 2010 Jul;34(8):1307-50. (PMID: 20398692)
Nature. 2010 Jan 28;463(7280):485-92. (PMID: 20110992)
Front Cell Neurosci. 2014 Dec 17;8:429. (PMID: 25565963)
Brain Res Brain Res Rev. 2001 Aug;36(1):60-90. (PMID: 11516773)
Pharmacol Biochem Behav. 2011 Aug;99(2):190-210. (PMID: 21315756)
J Cell Biol. 1995 Jun;129(6):1629-40. (PMID: 7790359)
FASEB J. 2014 Dec;28(12):5277-87. (PMID: 25205740)
Cereb Cortex. 1993 Nov-Dec;3(6):515-32. (PMID: 7511012)
Cell Motil Cytoskeleton. 2001 Jan;48(1):61-83. (PMID: 11124711)
Neurol Res. 2013 Oct;35(8):813-20. (PMID: 23651687)
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189. (PMID: 22229116)
Molecules. 2017 Mar 06;22(3):. (PMID: 28272324)
Trends Neurosci. 1991 Nov;14(11):501-6. (PMID: 1726767)
J Neurosci Methods. 1984 May;11(1):47-60. (PMID: 6471907)
Exp Neurol. 2000 Jan;161(1):15-26. (PMID: 10683270)
J Biol Chem. 1993 Aug 5;268(22):16679-87. (PMID: 8344946)
Neurobiol Learn Mem. 2003 Nov;80(3):194-210. (PMID: 14521863)
Mol Neurobiol. 2013 Feb;47(1):373-81. (PMID: 23054680)
J Mol Neurosci. 2014 Jun;53(2):222-30. (PMID: 24748327)
Brain Res. 2003 Oct 10;987(1):25-31. (PMID: 14499942)
Pharmacol Biochem Behav. 2009 Feb;91(4):554-9. (PMID: 18930076)
Science. 1982 Jul 30;217(4558):408-14. (PMID: 7046051)
J Mol Neurosci. 2016 Aug;59(4):579-89. (PMID: 27343058)
Exp Gerontol. 2011 Oct;46(10 ):836-40. (PMID: 21718780)
Exp Gerontol. 1977;12(1-2):7-11. (PMID: 885175)
Med Electron Microsc. 2000;33(4):173-99. (PMID: 11810476)
Mol Neurobiol. 2008 Aug;38(1):27-65. (PMID: 18649148)
Neurobiol Aging. 1981 Spring;2(1):3-8. (PMID: 6115325)
Curr Opin Neurobiol. 2006 Dec;16(6):710-5. (PMID: 17011181)
Psychopharmacology (Berl). 2013 Nov;230(2):245-60. (PMID: 23722831)
J Mol Neurosci. 2012 Jun;47(2):207-18. (PMID: 22415352)
Curr Opin Neurobiol. 1999 Oct;9(5):554-60. (PMID: 10508735)
Neuroscience. 2004;129(3):529-38. (PMID: 15541875)
Brain Res Bull. 2017 Jan;128:1-6. (PMID: 27818278)
J Neurotrauma. 1995 Oct;12(5):933-41. (PMID: 8594223)
Brain Pathol. 2016 Sep;26(5):581-92. (PMID: 26509872)
J Mol Neurosci. 2014 Sep;54(1):100-8. (PMID: 24573599)
J Cell Biol. 2000 Nov 27;151(5):1013-24. (PMID: 11086003)
Neural Regen Res. 2014 Oct 1;9(19):1731-9. (PMID: 25422633)
Lipids Health Dis. 2016 Aug 24;15(1):135. (PMID: 27558491)
Eur J Clin Invest. 1998 Nov;28(11):944-9. (PMID: 9824440)
BMC Complement Altern Med. 2014 Sep 17;14:338. (PMID: 25231482)
Brain Res Bull. 2016 Sep;126(Pt 3):324-333. (PMID: 27475416)
J Mol Neurosci. 2015 Aug;56(4):782-788. (PMID: 25645685)
-
Substance Nomenclature:
-
0 (Muscarinic Antagonists)
0 (Neurofilament Proteins)
DL48G20X8X (Scopolamine)
-
Entry Date(s):
-
Date Created: 20171220 Date Completed: 20180731 Latest Revision: 20181202
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC5780103
-
DOI:
-
10.3892/mmr.2017.8082
-
PMID:
-
29257227
-
Neurofilaments (NFs) including neurofilament‑200 kDa (NF‑H), neurofilament‑165 kDa (NF‑M) and neurofilament‑68 kDa (NF‑L) are major protein constituents of the brain, and serve important roles in the regulation of axonal transport. NF alteration is a key feature in the pathogenesis of neurological disorders involving cognitive dysfunction. In the present study, cognitive impairments were investigated, via assessments using the Morris water maze and passive avoidance tests, in mice following chronic systemic treatment with 1 mg/kg scopolamine (SCO) for 4 weeks. SCO‑induced cognitive impairments were significantly observed 1 week following the SCO treatment, and these cognitive deficits were maintained for 4 weeks. However, the NF immunoreactivities and levels were altered differently according to the hippocampal subregion following SCO treatment. NF‑H immunoreactivity and levels were markedly altered in all hippocampal subregions, and were significantly increased 1 week following the SCO treatment; thereafter, the immunoreactivity and levels significantly decreased with time. NF‑M immunoreactivity and levels gradually decreased in the hippocampus and were significantly decreased 4 weeks following SCO treatment. NF‑L immunoreactivity and levels gradually decreased in the hippocampus, and were significantly decreased 2 and 4 weeks following SCO treatment. In conclusion, the results of the present study demonstrated that chronic systemic treatment with SCO induced cognitive impairment from 1 week following SCO treatment, and NF expression was diversely altered according to the hippocampal subregion from 1 week following SCO treatment. These results suggest that SCO‑induced changes in NF expression may be associated with cognitive impairment.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
